AU2005233593B2 - Gene expression markers for predicting response to chemotherapy - Google Patents

Gene expression markers for predicting response to chemotherapy Download PDF

Info

Publication number
AU2005233593B2
AU2005233593B2 AU2005233593A AU2005233593A AU2005233593B2 AU 2005233593 B2 AU2005233593 B2 AU 2005233593B2 AU 2005233593 A AU2005233593 A AU 2005233593A AU 2005233593 A AU2005233593 A AU 2005233593A AU 2005233593 B2 AU2005233593 B2 AU 2005233593B2
Authority
AU
Australia
Prior art keywords
chemotherapy
expression
gene
breast cancer
likelihood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005233593A
Other languages
English (en)
Other versions
AU2005233593A1 (en
Inventor
Joffre B. Baker
Luca Gianni
Steven Shak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione IRCCS Istituto Nazionale dei Tumori
Genomic Health Inc
Original Assignee
Fondazione IRCCS Istituto Nazionale dei Tumori
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione IRCCS Istituto Nazionale dei Tumori, Genomic Health Inc filed Critical Fondazione IRCCS Istituto Nazionale dei Tumori
Publication of AU2005233593A1 publication Critical patent/AU2005233593A1/en
Application granted granted Critical
Publication of AU2005233593B2 publication Critical patent/AU2005233593B2/en
Priority to AU2010241525A priority Critical patent/AU2010241525B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005233593A 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy Expired AU2005233593B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010241525A AU2010241525B2 (en) 2004-04-09 2010-11-18 Gene expression markers for predicting response to chemotherapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56103504P 2004-04-09 2004-04-09
US60/561,035 2004-04-09
PCT/US2005/011760 WO2005100606A2 (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010241525A Division AU2010241525B2 (en) 2004-04-09 2010-11-18 Gene expression markers for predicting response to chemotherapy

Publications (2)

Publication Number Publication Date
AU2005233593A1 AU2005233593A1 (en) 2005-10-27
AU2005233593B2 true AU2005233593B2 (en) 2010-08-26

Family

ID=34981928

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005233593A Expired AU2005233593B2 (en) 2004-04-09 2005-04-07 Gene expression markers for predicting response to chemotherapy
AU2010241525A Expired AU2010241525B2 (en) 2004-04-09 2010-11-18 Gene expression markers for predicting response to chemotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010241525A Expired AU2010241525B2 (en) 2004-04-09 2010-11-18 Gene expression markers for predicting response to chemotherapy

Country Status (9)

Country Link
US (2) US7871769B2 (enExample)
EP (4) EP2270232A1 (enExample)
JP (3) JP5813908B2 (enExample)
AU (2) AU2005233593B2 (enExample)
CA (2) CA2563074C (enExample)
DK (1) DK2163650T3 (enExample)
ES (2) ES2550614T3 (enExample)
IL (4) IL178508A (enExample)
WO (1) WO2005100606A2 (enExample)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
JP5139811B2 (ja) * 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドセタキセル耐性または感受性の測定方法
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2008017832A (ja) * 2006-06-13 2008-01-31 Sysmex Corp がんの転移の判定方法及び判定装置
US20080076134A1 (en) * 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008098086A2 (en) * 2007-02-06 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A gene expression profile that predicts ovarian cancer subject response to chemotherapy
DK2134374T3 (en) * 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
EP2140020A2 (en) * 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
JP2009050189A (ja) * 2007-08-24 2009-03-12 Sumitomo Bakelite Co Ltd 抗癌剤の有効性予測方法
US20100196902A1 (en) * 2007-09-14 2010-08-05 Gary Pestano Prostate cancer biomarkers
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
WO2009137664A1 (en) * 2008-05-07 2009-11-12 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of bcl-2 family and uses thereof
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
WO2010007083A2 (en) * 2008-07-15 2010-01-21 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
KR100996994B1 (ko) * 2008-08-18 2010-11-25 울산대학교 산학협력단 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법
JP2012500631A (ja) * 2008-08-20 2012-01-12 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド， ア ボディー コーポレイト Ｉｇｆ−１ｒ処置に対する癌の感受性を評価するためのマーカー
JP2010057486A (ja) * 2008-09-02 2010-03-18 Sysmex Corp 化学療法に対するがん患者の応答の予測方法
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
EP2373809A1 (en) * 2008-12-10 2011-10-12 Ipsogen Methods for identifying erbb2 alteration in tumors
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US12680139B2 (en) 2009-01-07 2026-07-14 Myriad Genetics, Inc. Cancer biomarkers
CA2751688A1 (en) * 2009-02-06 2010-08-12 Biao He Emx2 in cancer diagnosis and prognosis
US8972899B2 (en) 2009-02-10 2015-03-03 Ayasdi, Inc. Systems and methods for visualization of data analysis
WO2010121231A1 (en) * 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2588864A1 (en) * 2010-07-02 2013-05-08 Topogen Inc. Method for diagnosis of bladder cancer and related kits
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
TW201209163A (en) * 2010-07-12 2012-03-01 Opko Curna Llc Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
MX350533B (es) 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
ES2816625T3 (es) 2010-09-24 2021-04-05 Niels Grabe Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP5828446B2 (ja) * 2011-02-10 2015-12-09 国立大学法人秋田大学 扁平上皮癌組織の放射線感受性マーカー
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
US20130042333A1 (en) * 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
WO2012174203A2 (en) * 2011-06-14 2012-12-20 Anthony Albino Methods and kits for the detection and treatment of recurring prostate cancer
EP2834640B1 (en) * 2011-10-04 2020-06-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
EP2766836A4 (en) * 2011-10-10 2015-07-15 Ayasdi Inc SYSTEM AND METHOD FOR ALLOCATING NEW PATIENT INFORMATION TO PREVIOUS RESULTS IN SUPPORT OF TREATMENT
WO2013082440A2 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2794924B1 (en) 2011-12-22 2019-02-06 Baylor Research Institute Identification of mirna signatures in human colorectal cancer
WO2013109690A1 (en) * 2012-01-17 2013-07-25 Myriad Genetics, Inc. Breast cancer prognosis signatures
MX351626B (es) 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
FR2987446B1 (fr) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis Test diagnostic de la resistance a l'azacitidine
WO2013170174A1 (en) 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
EP2863920B1 (en) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Quinoline derivatives for use in the tratment of breast cancer
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014085653A1 (en) * 2012-11-30 2014-06-05 Celera Corporation Multi-gene signatures for predicting response to chemotherapy or risk of metastasis for breast cancer
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
US10240206B2 (en) * 2013-02-01 2019-03-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Biomarkers and methods for predicting benefit of adjuvant chemotherapy
US10041125B2 (en) 2013-03-15 2018-08-07 Janssen Pharmaceutica Nv Assay for predictive biomarkers
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
SI3134119T1 (sl) * 2014-04-24 2018-11-30 Pfizer Inc. Zdravljenje raka
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
CA2965217A1 (en) * 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US11610644B2 (en) 2014-10-24 2023-03-21 Koninklijke Philips N.V. Superior bioinformatics process for identifying at risk subject populations
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
KR102116485B1 (ko) 2015-01-20 2020-05-28 난토믹스, 엘엘씨 고분화 방광암의 화학요법에 대한 반응 예측을 위한 시스템들 및 방법들
EP3362563A1 (en) 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
EP3387443A4 (en) * 2015-12-10 2019-11-13 Nantomics, LLC INTEGRATED ANALYSIS TO DETERMINE PROGNOSIS AFTER THE TREATMENT OF PRIMARY BREAST CANCER
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
SG11201901667TA (en) 2016-09-16 2019-03-28 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
WO2018195249A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
RU2675236C1 (ru) * 2018-02-22 2018-12-18 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных раком молочной железы
JP2021522848A (ja) 2018-05-15 2021-09-02 オンコロジー ベンチャー アーペーエス 癌患者における薬物応答性を予測する方法
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
US20220357328A1 (en) * 2019-09-09 2022-11-10 Oaklabs Gmbh Superior biomarker signature to predict the response of a breast cancer patient to chemotherapy
CN111184865B (zh) * 2020-03-09 2021-11-16 复旦大学附属金山医院 Stat1在耐紫杉醇上皮性卵巢癌治疗中的用途
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
EP4623092A1 (en) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease
WO2025171441A1 (en) * 2024-02-13 2025-08-21 The Council Of The Queensland Institute Of Medical Research Prognostic signature for cancer recurrence and responsiveness

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
JP3944241B2 (ja) * 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Ａｕｒ―１および／またはａｕｒ―２関連疾患の診断および処置
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
DE19922052A1 (de) * 1999-05-14 2000-11-16 Theragen Molekularmedizinische Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
WO2001025250A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2391455A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) * 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001055448A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US7157227B2 (en) * 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002008765A2 (en) 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP4368110B2 (ja) * 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
EP1425302A2 (en) 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
EP1379694B1 (en) * 2001-03-01 2006-05-10 Epigenomics AG Methods and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
KR20030094281A (ko) 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20030077582A1 (en) * 2001-03-27 2003-04-24 Wen-Lin Kuo Methods for diagnosing and monitoring malignancies by screeining gene copy numbers
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
PT1410011E (pt) 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
CN1612936A (zh) * 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20030124130A1 (en) * 2002-01-02 2003-07-03 Brown Robert E. Proteomic analysis of tumors for development of consultative report of therapeutic options
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1900827A3 (en) 2002-05-21 2008-04-16 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DE602004017426D1 (de) 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US10066268B2 (en) 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
EP1759009A1 (en) * 2004-05-28 2007-03-07 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
DK1974058T3 (da) 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
EP2140020A2 (en) 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009026128A2 (en) 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
DK2294215T3 (da) 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
EP2425020A4 (en) 2009-05-01 2016-04-20 Genomic Health Inc GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY
EP4350001A3 (en) 2009-11-23 2024-06-19 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients

Also Published As

Publication number Publication date
WO2005100606A3 (en) 2006-06-22
IL178508A (en) 2011-11-30
IL244249A0 (en) 2016-04-21
JP6130726B2 (ja) 2017-05-17
IL214994A0 (en) 2011-10-31
CA2563074C (en) 2014-05-20
CA2848463A1 (en) 2005-10-27
IL244249A (en) 2017-04-30
JP5813908B2 (ja) 2015-11-17
IL214994A (en) 2013-02-28
US7871769B2 (en) 2011-01-18
US9605318B2 (en) 2017-03-28
JP2007532113A (ja) 2007-11-15
AU2005233593A1 (en) 2005-10-27
JP2013176388A (ja) 2013-09-09
US20110129833A1 (en) 2011-06-02
EP2163650A1 (en) 2010-03-17
IL214995A0 (en) 2011-10-31
AU2010241525A1 (en) 2010-12-09
EP2163650B1 (en) 2015-08-05
CA2563074A1 (en) 2005-10-27
EP2947160A1 (en) 2015-11-25
HK1217737A1 (en) 2017-01-20
WO2005100606A2 (en) 2005-10-27
JP6190434B2 (ja) 2017-08-30
JP2016041071A (ja) 2016-03-31
AU2010241525B2 (en) 2011-07-21
IL214995A (en) 2016-03-31
EP2270232A1 (en) 2011-01-05
ES2550614T3 (es) 2015-11-11
EP2947160B1 (en) 2017-07-12
EP1737980A2 (en) 2007-01-03
IL178508A0 (en) 2007-02-11
ES2636470T3 (es) 2017-10-05
DK2163650T3 (en) 2015-11-02
US20050260646A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
AU2010241525B2 (en) Gene expression markers for predicting response to chemotherapy
AU2004248120B2 (en) Gene expression markers for predicting response to chemotherapy
EP1836629B1 (en) Predicting response to chemotherapy using gene expression markers
EP2775000A1 (en) Prediction of likelihood of cancer recurrence
JP2006516897A (ja) 乳癌予後診断のための遺伝子発現マーカー
AU2011204944B2 (en) Gene expression markers for predicting response to chemotherapy
AU2012200431B2 (en) Gene expression markers for predicting response to chemotherapy
HK1217737B (en) Gene expression markers for predicting response to chemotherapy
KR20070022694A (ko) 화학요법 반응을 예측하기 위한 유전자 발현 마커

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired